Mar. 20 at 7:22 PM
$AUPH
cont’d
“Looking to the future, M&A negotiations may only get more intense, as available companies with Phase 3 assets have mostly been picked off. Henry said that pharmas are having to look earlier, with Phase 2 becoming a major battleground. Typically risk-averse Big Pharmas may need to start thinking even earlier,” Henry said.
“The supply of ready-to-go assets with on-market products and clear Phase 3 pipelines dwindles more and more every day.”
So, FDA approved products and a molecule pipeline are the biotechs with a full ‘dance card’, sticking with the same theme in the article.
Under competent leadership, AUPH could be looking purdy …
https://www.biospace.com/business/pharma-is-ravenous-for-m-a-action-but-late-stage-supply-dwindles
